Ensign Peak Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.2M Buy
83,099
+10,147
+14% +$3.36M 0.04% 306
2026
Q2
$24.4M Buy
72,952
+4,569
+7% +$1.45M 0.04% 281
2026
Q1
$22M Buy
68,383
+4,100
+6% +$1.27M 0.04% 292
2025
Q4
$18.9M Buy
+64,283
New +$12M 0.03% 302
2025
Q1
– Sell
-27,650
Closed -$2.13M – 1717
2024
Q4
$2.13M Buy
+27,650
New +$2M ﹤0.01% 911
2022
Q2
– Sell
-291
Closed -$45K – 2195
2022
Q1
$45K Hold
291
– – ﹤0.01% 2136
2021
Q4
$86K Buy
+291
New +$85.3K ﹤0.01% 2087

Other funds holding PRAX

Ensign Peak Advisors's PRAX Position: Q3 2026 in Review

Ensign Peak Advisors increased its Praxis Precision Medicines (PRAX) stake by 14% in Q3 2026, buying an estimated $3.36M and bringing the position to 83,099 shares worth $24.2M. The position accounts for 0.04% of the portfolio, ranked #306.

Ensign Peak Advisors first reported a position in PRAX in Q4 2021 and has held it in 7 quarters since. The position peaked at $24.4M in Q2 2026. 329 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

  • Ensign Peak Advisors held 83,099 shares of Praxis Precision Medicines worth $24.2M as of Q3 2026.
  • Ensign Peak Advisors bought 10,147 Praxis Precision Medicines shares in Q3 2026, an estimated $3.36M.
  • Praxis Precision Medicines made up 0.04% of Ensign Peak Advisors's portfolio in Q3 2026, its #306 holding.
  • Ensign Peak Advisors first reported a position in Praxis Precision Medicines in Q4 2021 and has held it in 7 quarters since.
  • Ensign Peak Advisors's Praxis Precision Medicines position peaked at $24.4M in Q2 2026.
  • 329 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.